Precision Biosciences (DTIL) Net Cash Flow (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Net Cash Flow data on file, last reported at -$11.3 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$11.3 million, down 30.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.1 million (up 168.62% YoY), and the FY2025 annual result was $28.7 million, up 449.39% from the prior year.
• Net Cash Flow retreated to -$11.3 million in Q1 2026 per DTIL's latest filing, from $65.9 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $67.9 million in Q2 2022 and troughed at -$31.4 million in Q1 2023.
• A 5-year average of -$1.0 million and a median of -$12.9 million in 2024 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 612.76% in 2025 and fell as far as 506.06% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$22.5 million in 2022, then jumped by 75.29% to -$5.6 million in 2023, then slumped by 131.59% to -$12.9 million in 2024, then surged by 612.76% to $65.9 million in 2025, then slumped by 117.15% to -$11.3 million in 2026.
• Business Quant data shows DTIL's Net Cash Flow at -$11.3 million in Q1 2026, $65.9 million in Q4 2025, and -$13.6 million in Q3 2025.